Steven Mackey, MD
Internal Medicine · New York, NYNPI 1700984648
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,627 of the $5,227 with a category attached, or 69.4%. 12 manufacturers reported payments, led by Novo Nordisk at 32.3% of the total. Reporting peaked in 2019 at $2,721 and has fallen 81.1% since, to $515 in 2025. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 65 payments — averaging $80.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Otsuka America Pharmaceutical, Inc.$2K
- Merck$489
- Boehringer Ingelheim$354
- Esperion Therapeutics, Inc.$250
- AstraZeneca$230
- plus $625 from 6 others
What the payments were for
- Consulting fees$1,59030%
- Food & beverage$3,62769%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 22 | $1,689 |
| Otsuka America Pharmaceutical, Inc. | 1 | $1,590 |
| Merck | 19 | $489 |
| Boehringer Ingelheim | 8 | $354 |
| Esperion Therapeutics, Inc. | 2 | $250 |
| AstraZeneca(2 entities) | 2 | $230 |
| Amgen | 4 | $176 |
| Sanofi-aventis U.S. LLC | 1 | $142 |
| Mannkind Corporation | 1 | $125 |
| Lilly USA, LLC | 3 | $120 |
| Insulet Corporation | 1 | $44 |
| Genentech USA, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,227 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 14 | $11,357 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 25 | $817 |
| Atorvastatin Calcium | 45 | $621 |
| Diclofenac Sodium | 14 | $194 |
| Losartan Potassium | 21 | $165 |
| Amlodipine Besylate | 24 | $161 |
| Pantoprazole Sodium | 17 | $154 |
| Gabapentin | 16 | $130 |
| Rosuvastatin Calcium | 12 | $110 |
| Carvedilol | 21 | $99 |
| Metformin Hcl | 13 | $66 |
| Lisinopril | 11 | $40 |
| Meloxicam | 12 | $38 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in New York
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
- Terry PlasseNew York$883K
- Krisczar BungayNew York$554K
- Eytan SteinNew York$496K
- Larry NeumanNew York$457K
- Wuhua JingNew York$338K
- Harvey SchneienNew York$334K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.